Cureport, Inc., Massachusetts, United States
Keywords: Liposome formulations, nanotechnology, cardio renal toxicity, cancer, drug resistant microbialThe cardio and renal toxicities of anti-cancer and anti-microbial drugs are life-threatening risks to the patients. Liposomes are clinically proven as drug carriers to reduce the toxicity and enhance the efficacy of medicines. However, the development of liposomal drugs was badly hindered by the tedious manufacturing process. Recently we have invented the nPort technology; it brought a breakthrough to the liposomal pharmaceutical industry. The robustness of nPort technology in liposome homogeneity, reproducibility, continuous particle size control from 20 to 200 nm, and the straightforward commercial scalability enabled Cureport to quickly established its own pharmaceutical pipelines. The APIs encapsulated in the liposomes include small molecules, peptides, and siRNAs/mRNAs. This poster reports the physicochemical properties and promising biologic results of carfilzomib and polymyxin B liposomal formulations. Carfilzomib is a recently approved medicine for multiple myeloma treatment; it improves overall survival rate of patients but causes severe cardio toxicity. Polymyxin B is the last resort against MDR gram-negative bacteria, despite the huge risk of its renal toxicity to patients. Our preliminary¬¬ data showed that Cureport’s liposome formulations eliminated the toxicities of carfilzomib and polymyxin B, and improved the efficacy as well.